Ibrahim Al-khyate։ New Evidence on Triple Antithrombotic Therapy After Anterior Myocardial Infarction
Ibrahim Al-khyate, Cardiology Resident at Ministry of Health and Population – Egypt, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Clinical and Applied Thrombosis/Hemostasis, adding:
”Excited to share our latest publication in Clinical and Applied Thrombosis/Hemostasis!
Our updated systematic review and meta-analysis has now been published in SAGE Journals.
7 studies | 2,273 patients
Research question
Does adding prophylactic triple antithrombotic therapy to dual antiplatelet therapy after anterior myocardial infarction reduce the risk of left ventricular thrombus without compromising patient safety?
Main findings
- No significant reduction in left ventricular thrombus
- No reduction in all-cause mortality
- No reduction in thromboembolic events
Increased risk of major bleeding
Take-home message:
Current evidence does not support the routine use of prophylactic triple antithrombotic therapy after anterior myocardial infarction.
Antithrombotic therapy should be individualized, balancing thrombotic and bleeding risks.
Sincerely grateful to my co-authors and mentors for their dedication, insightful discussions, and collaboration throughout this project.
Looking forward to future collaborations and continuing to contribute to meaningful cardiovascular research.”
Title: Triple Antithrombotic Therapy vs Dual Antiplatelet for Prevention of Left Ventricular Thrombus After Anterior Myocardial Infarction: An Updated Meta-Analysis
Authors: Mustafa Abomohsen, Ibrahim Elkhayat, Ahmed Elmorsy Mohamed, Abdul Hakim Almakadma, Zeyad Kholeif, Ahmed Farid Gadelmawla, Ameer Awashra, Muhammed A. Youssef, Osamah AlQassab, Mohamed Ghannam, Vikas Patel, Azad Mojahedi, Iyad Idries, Meena Farid, Moshe Gunsburg, Hal L. Chadow
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 11:15Bridging Neurology and Thrombosis: Key Priorities from a New Expert Consensus Report – International Journal of Stroke
-
Aug 13, 2026, 11:05Khaled Musallam: The Evolving Landscape of β-Thalassemia: Clinical Trial Advances Since 2021
-
Aug 13, 2026, 10:31Brad Wilson: Clinical Insights from the Landmark ESC 2026 Trials
-
Aug 13, 2026, 10:23Rania Baleela: Evaluating Bedside Diagnostics and VICC Outcomes in Hemotoxic Snakebite
-
Aug 13, 2026, 10:11Christina Kounoudi: Low-Dose vs. Therapeutic Anticoagulation in Extended VTE Prophylaxis
-
Aug 13, 2026, 10:10Jean Connors: Can Prothrombin Levels Improve Antiphospholipid Syndrome Risk Assessment?
-
Aug 13, 2026, 09:44Edward Lee Carter: Why Clinically Relevant Nonmajor Bleeding Demands Anticoagulation Stewardship?
-
Aug 13, 2026, 09:40Neel Bhut: Can AI Help Us Make Gene Therapy More Efficient?
-
Aug 13, 2026, 08:23Sally Mandour: The Diagnostic Challenge of Hypocellular Bone Marrow Failure